To acquire the complete package would stack the deck in any of the biopharmas, but until that deal is made (for which the phase 2a results have already provided efficacy data) licensing deals are an open market for profiteering IMHO.
With such a tightly jigged ship, their top priority of two licensing deals in 2014 can be assumed to come into play without notice.
BBY valued 0.12c low, 0.17c high on previous market knowledge, A "3-4 bagger".
Things have only improved for the company since then. . .
To acquire the complete package would stack the deck in any of...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |